| Popis: |
Progress is reported on: metabolic and tumor localization in man and animals; radiodrug development; dosimetry for internally deposited isotopes; and radioactive material transfer system. Based on experience with /sup 13/N-glutamate in osteogenic sarcoma and Ewing's sarcoma, we conclude that (a) the /sup 13/N label enters tumor tissue rapidly at a rate similar to that at which activity leaves the blood, suggesting that the labeled glutamate itself is being transported into the tumor rather than some labeled metabolite; (b) uptake in the tumor is related to its metabolic activity, but factors such as blood flow are also important; (c) changes in the glutamate scan accurately reflect the response of osteogenic sarcoma to pre-operative chemotherapy as measured by conventional means, and that it is desirable to extend this experience to other types of tumors. /sup 13/N-Glutamate (and other /sup 13/N-labeled compounds) afford several advantages over conventional tumor imaging agents, such as rapid blood clearance and localization, low radiation exposure and the possibility of obtaining accurate, three-dimensional quantitative images via positron emission tomography. It is doubtful that these advantages will justify the routine use of /sup 13/N-glutamate to detect tumors or to monitor therapy except in clinical situations where conventional techniques are unsatisfactory.more » The value of /sup 1/3N-glutamate is as a tool to assess the metabolic requirement of neoplastic tissue in cancer patients in-vivo. (PCS)« less |
